Condition: Chronic Graft-Versus-Host Disease (cGVHD) · Sponsor: Deciphera Pharmaceuticals, LLC
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
This description comes directly from the study's public registry record.
Clinical Team · 888-724-3274 · clinicaltrials@deciphera.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Ronald Regan UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| University of California Irvine Health | Orange, California, United States | Recruiting |
| AdventHealth Orlando | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Emory University Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| University of Illinois Medical Center - Hematology & Oncology | Chicago, Illinois, United States | Recruiting |
| University of Kansas Cancer Center-Westwood | Westwood, Kansas, United States | Recruiting |
| University of Kentucky Markey Cancer Center | Lexington, Kentucky, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Washington University School of Medicine - Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06619561